Profound Medical (NASDAQ:PROF – Get Free Report) and Femasys (NASDAQ:FEMY – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk. Valuation and Earnings This table compares Profound Medical […]
Timelo Investment Management Inc. lessened its position in Profound Medical Corp. (NASDAQ:PROF – Free Report) by 9.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 611,758 shares of the company’s stock after selling 61,400 shares during the quarter. Profound Medical makes up about […]
Letko Brosseau & Associates Inc. reduced its stake in Profound Medical Corp. (NASDAQ:PROF – Free Report) by 0.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,164,125 shares of the company’s stock after selling 4,150 shares during the quarter. Letko Brosseau & Associates Inc. […]
Profound Medical (NASDAQ:PROF – Get Free Report) and BlueRiver Acquisition (NYSE:BLUA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability. Earnings & Valuation This table compares Profound […]
Profound Medical Corp. (NASDAQ:PROF – Free Report) – Analysts at Raymond James issued their Q1 2025 earnings per share (EPS) estimates for Profound Medical in a report released on Thursday, January 25th. Raymond James analyst R. Sarugaser forecasts that the company will earn ($0.21) per share for the quarter. The consensus estimate for Profound Medical’s […]